HEALTH PROFESSIONAL · SOURCE READING

ROS1-directed therapy

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Progressive Stage IV, Relapsed, and Recurrent NSCLC / Treatment Options for Progressive Stage IV, Relapsed, and Recurrent NSCLC (Second-Line Therapy)

ROS1 rearrangements occur in approximately 1% to 2% of patients with NSCLC.[41] ROS1 TKI therapy is the current standard of care for patients with locally advanced or metastatic NSCLC and ROS1 variants. Crizotinib, entrectinib, and repotrectinib are all approved by the FDA for patients with NSCLC with ROS1 fusions. Notably, repotrectinib is the only ROS1 TKI that is approved by the FDA for patients previously treated with a ROS1 TKI. Repotrectinib also appears to be active in patients with brain metastases and ROS1 G2032R resistance variants.

Source links and citations

Continue within this section

Entrectinib →Crizotinib →Repotrectinib (for both ROS1 TKI-naïve and ROS1 TKI-treated patients) →

Publication references

Read the original reference and check its publication notices.

PubMed 23814043 · Original source

Preserved source evidence · Not medical advice